Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
20416
Hu C, Yang L, Wang Y, Zhou S, Luo J, Gu Y.
Ginsenoside Rh2 reduces m6A RNA methylation in cancer via the KIF26B-SRF positive feedback loop.J Ginseng Res
2021
45(6):734-743
PubMed ID: 34764728
DOI: 10.1016/j.jgr.2021.05.004
12076
Kawarazaki A, Horinaka M, Yasuda S, Kawashima H, Numajiri T, Sakai T.
The HDAC inhibitor OBP-801 suppresses the growth of myxofibrosarcoma cells.J BUON
2020
PubMed ID: 32277670
14821
Shiraishi D, Fujiwara Y, Horlad H, Saito Y, Iriki T, Tsuboki J, Cheng P, Nakagata N, Mizuta H, Bekki H, Nakashima Y, Oda Y, Takeya M, Komohara Y.
CD163 Is Required for Protumoral Activation of Macrophages in Human and Murine SarcomaCancer Res
2018
78(12):3255-3266
PubMed ID: 29610117
DOI: 10.1158/0008-5472.CAN-17-2011